EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Onset of Action of Azelastine 0.15% Versus Olopatadine/Mometasone for Allergen‐Induced Rhinitis: An EEU Crossover Study

Jean Bousquet iD, Ludger Klimek iD, Hans-Christian Kuhl, Duc Tung Nguyen, Rajesh Kumar iD, William E Berger iD

Clinical and Translational Allergy · 2026-11 · 16 (11)

DOI: 10.1002/clt2.70213 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Allergy, online erschienen am 08.11.2026. Verfasst von Jean Bousquet und 5 weiteren Autor:innen. Beteiligte Einrichtung: Immunology and Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Viatris.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The aim of this study was to compare the onset of action (primary), and overall efficacy (secondary) of azelastine nasal spray 0.15% (AZE 0.15%) with mometasone/olopatadine combination therapy (OloMom) in subjects with allergen‐induced rhinitis under controlled allergen exposure conditions in an Environmental Exposure Unit (EEU).

Method

This was a randomized, double‐blind, placebo‐controlled, three‐period Williams cross‐over study. Participants were randomized to receive AZE 0.15%, OloMom, or placebo. Efficacy was assessed during two pollen challenge sections in an EEC, after a single dose and after 3.5 days of treatment. Following a minimum 14‐day washout period, subjects received alternate treatment and repeated study procedures until all three interventions were evaluated. The primary endpoint was time to onset of action based on change from baseline in Total Nasal Symptom Score (TNSS). Secondary assessments included total and individual nasal and ocular symptoms and overall efficacy after 3.5 days of treatment.

Results

Eighty‐four subjects completed the study (mean age 41.5 years; balanced sex distribution), all with confirmed ragweed sensitivity. All treatments reduced TNSS post‐dose, with most effective and fastest relief from AZE 0.15%, onset at 15 minutes, sensitivity analyses supported onset at 10 minutes, and greater early nasal, ocular, and total symptom relief compared to OloMom and placebo.

Conclusion

AZE 0.15% delivered rapid and clinically significant relief of AR, demonstrating greater early symptoms improvement compared with OloMom. Overall efficacy was comparable between treatments, supporting AZE 0.15% as an effective, steroid‐free alternative for rapid symptom control in patients with pollen allergies.

Schlagwörter

Stichwörter der Autor:innen

AZE 0.15%Environmental Exposure Unitallergic rhinitisnasal and ocular symptoms

Autor:innen und Institutionen

  • Immunology and Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany.
  • Institute of Allergology, Charité-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Department of Otolaryngology, Head and Neck Surgery, Universitätsmedizin Mainz, Mainz, Germany.
  • Center for Rhinology and Allergology, Wiesbaden, Germany.
  • Biometrics, Meda Pharma GmbH & Co KG (A Viatris Company), Bad-Homburg, Germany.
  • Global Clinical Sciences, MEDA Pharma GmbH & Co KG (A Viatris Company), Bad Homburg, Germany.

ORCID-Profile: Jean Bousquet, Ludger Klimek, Rajesh Kumar, William E Berger

Förderung

  • Viatris

Zitieren

APA

Bousquet, J., Klimek, L., Kuhl, H. C., Nguyen, D. T., Kumar, R., & Berger, W. E. (2026). Onset of Action of Azelastine 0.15% Versus Olopatadine/Mometasone for Allergen‐Induced Rhinitis: An EEU Crossover Study. Clinical and Translational Allergy, 16(11). https://doi.org/10.1002/clt2.70213

Vancouver

Bousquet J, Klimek L, Kuhl HC, Nguyen DT, Kumar R, Berger WE. Onset of Action of Azelastine 0.15% Versus Olopatadine/Mometasone for Allergen‐Induced Rhinitis: An EEU Crossover Study. Clinical and Translational Allergy. 2026;16(11). doi:10.1002/clt2.70213

BibTeX
@article{Bousquet2026,
  author = {Bousquet, Jean and Klimek, Ludger and Kuhl, Hans-Christian and Nguyen, Duc Tung and Kumar, Rajesh and Berger, William E},
  title = {Onset of Action of Azelastine 0.15% Versus Olopatadine/Mometasone for Allergen‐Induced Rhinitis: An EEU Crossover Study},
  journal = {Clinical and Translational Allergy},
  year = {2026},
  volume = {16},
  number = {11},
  doi = {10.1002/clt2.70213}
}
Kostenlos starten →